Watson Confirms Favorable Appeals Court Decision in Sanctura XR® Patent Suit
PARSIPPANY, N.J., June 18, 2012
PARSIPPANY, N.J., June 18, 2012 /PRNewswire/ --Watson Pharmaceuticals, Inc.
(NYSE: WPI) today confirmed thatthe United StatesCourt of Appeals for the
Federal Circuit has affirmed the United States District Court for the District
of Delaware'sMarch 31, 2012 decision that the asserted claims of U.S. Patent
Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to
Sanctura XR® (trospium chloride extended-release capsules) are invalid.
Watson's Abbreviated New Drug Application for a generic version of Sanctura
XR® is pending with theFood and Drug Administration.
Sanctura XR® is indicated for the treatment of overactive bladder (OAB) with
symptoms of urge urinary incontinence, urgency and urinary frequency. For the
twelve months ending April 30, 2012, Sanctura XR® had total U.S. sales of
approximately $66 million, according to IMS Health data.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc.is an integrated global specialty pharmaceutical
company. The Company is engaged in the development, manufacturing, marketing
and distribution of generic pharmaceuticals and specialized branded
pharmaceutical products focused on Urology and Women's Health. The Company is
also developing biosimilar products in Women's Health and Oncology.
Additionally, Watson distributes generic and branded pharmaceuticals through
itsAnda, Inc. distribution business. Watson has operations in many of the
world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals'
Web site at http://www.watson.com.
Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Watson's current perspective of
existing information as of the date of this release. It is important to note
that Watson's goals and expectations are not predictions of actual
performance. Actual results may differ materially from Watson's current
expectations depending upon a number of factors, risks and uncertainties
affecting Watson's business. These factors include, among others, the
difficulty of predicting the timing or outcome of product development efforts,
including FDA and other regulatory agency approvals and actions, if any; the
impact of competitive products and pricing; the timing and success of product
launches; difficulties or delays in manufacturing; the availability and
pricing of third party sourced products and materials; successful compliance
with FDA and other governmental regulations applicable to Watson and its third
party manufacturers' facilities, products and/or businesses; changes in the
laws and regulations, including Medicare and Medicaid, affecting among other
things, pricing and reimbursement of pharmaceutical products; and such other
risks and uncertainties detailed in Watson's periodic public filings with the
Securities and Exchange Commission, including but not limited to Watson's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and
Watson's Annual Report on Form 10-K for the year ended December 31, 2011.
Except as expressly required by law, Watson disclaims any intent or obligation
to update these forward-looking statements.
Sanctura XR® is a registered trademark of Allergan, Inc.
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )
SOURCE Watson Pharmaceuticals, Inc.
Contact: Investors: Lisa DeFrancesco, +1-862-261-7152; or Media: Charlie Mayr,
Press spacebar to pause and continue. Press esc to stop.